Compare RDW & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | XERS |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2020 | 2021 |
| Metric | RDW | XERS |
|---|---|---|
| Price | $8.98 | $10.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $14.28 | $12.86 |
| AVG Volume (30 Days) | ★ 9.4M | 2.5M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.98 | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $335,381,000.00 | $49,590,000.00 |
| Revenue This Year | $41.71 | $32.91 |
| Revenue Next Year | $18.75 | $23.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 10.29 | ★ 142.67 |
| 52 Week Low | $4.87 | $5.25 |
| 52 Week High | $26.64 | $11.42 |
| Indicator | RDW | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 56.97 |
| Support Level | $8.39 | $9.73 |
| Resistance Level | $10.43 | $10.60 |
| Average True Range (ATR) | 0.53 | 0.48 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 47.40 | 41.25 |
Redwire Corp is an integrated space and defense technology company focused on technologies including aerospace infrastructure, autonomous systems and multi-domain operations, leveraging digital engineering and artificial intelligence automation. The Company develops and provides mission critical solutions based on space and defense technology platform offerings for government, commercial and civil customers through both short- and long-duration projects. These include technologies and production capability for next-generation spacecraft, large space infrastructure, microgravity capabilities, combat autonomous systems, optical sensors and radio frequency payloads that provide intelligence, surveillance, and reconnaissance capabilities for U.S. and allied nations across multiple domains.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.